National trends in ambulatory oral anticoagulant use

American Journal of Medicine

Volumn 128, Issue 12, 2015, Pages 1300-1305.e2

  Barnes, Geoffrey D ^a   Lucas, Eleanor ^b   Alexander, G Caleb ^b   Goldberger, Zachary D ^c  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Anticoagulants; Atrial Fibrillation; Venous Thromboembolism; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; DOCTOR PATIENT RELATION; DRUG INDICATION; DRUG USE; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; VENOUS THROMBOEMBOLISM; ADULT; AGE; AGED; AMBULATORY CARE; CLINICAL PRACTICE; COMPLICATION; EPIDEMIOLOGY; FEMALE; MALE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PROCEDURES; STATISTICS AND NUMERICAL DATA; UNITED STATES; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; AGE FACTORS; AGED; AMBULATORY CARE; ANTICOAGULANTS; ATRIAL FIBRILLATION; DABIGATRAN; FEMALE; HUMANS; MALE; MIDDLE AGED; PRACTICE PATTERNS, PHYSICIANS'; PYRAZOLES; PYRIDONES; RIVAROXABAN; UNITED STATES; VENOUS THROMBOEMBOLISM; WARFARIN; YOUNG ADULT;

EID: 84947865925     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2015.05.044     Document Type: Article

References (38)

1. N.J. Patel, A. Deshmukh, S. Pant, and et al. Contemporary trends of hospitalization for atrial fibrillation in the United States, 2000 through 2010: implications for healthcare planning Circulation 129 23 2014 2371 2379
2. S.S. Chugh, R. Havmoeller, K. Narayanan, and et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study Circulation 129 8 2014 837 847
3. C.E. Mahan, M.E. Borrego, A.L. Woersching, and et al. Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates Thromb Haemost 108 2 2012 291 302
4. G.D. Barnes, W. Ageno, J. Ansell, and S. Kaatz Subcommittee on the Control of A Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH J Thromb Haemost 2015
5. I.M. Ogilvie, N. Newton, S.A. Welner, W. Cowell, and G.Y. Lip Underuse of oral anticoagulants in atrial fibrillation: a systematic review Am J Med 123 7 2010 638 645.e4
6. D. Mozaffarian, E.J. Benjamin, A.S. Go, and et al. Heart disease and stroke statistics-2015 update: a report from the American Heart Association Circulation 131 4 2015 e29 322
7. K. Kirley, D.M. Qato, R. Kornfield, R.S. Stafford, and G.C. Alexander National trends in oral anticoagulant use in the United States, 2007 to 2011 Circ Cardiovasc Qual Outcomes 5 5 2012 615 621
8. G.C. Alexander, N.L. Sehgal, R.M. Moloney, and R.S. Stafford National trends in treatment of type 2 diabetes mellitus, 1994-2007 Arch Intern Med 168 19 2008 2088 2094
9. R.S. Stafford, C.D. Furberg, S.N. Finkelstein, I.M. Cockburn, T. Alehegn, and J. Ma Impact of clinical trial results on national trends in alpha-blocker prescribing, 1996-2002 JAMA 291 1 2004 54 62
10. R.S. Stafford, and D.C. Radley The underutilization of cardiac medications of proven benefit, 1990 to 2002 J Am Coll Cardiol 41 1 2003 56 61
11. K. Lang, D. Bozkaya, A.A. Patel, and et al. Anticoagulant use for the prevention of stroke in patients with atrial fibrillation: findings from a multi-payer analysis BMC Health Serv Res 14 2014 329
12. J. Robson, I. Dostal, R. Mathur, and et al. Improving anticoagulation in atrial fibrillation: observational study in three primary care trusts Br J Gen Pract 64 622 2014 e275 e281
13. L. Gorin, L. Fauchier, E. Nonin, B. Charbonnier, D. Babuty, and G.Y. Lip Prognosis and guideline-adherent antithrombotic treatment in patients with atrial fibrillation and atrial flutter: implications of undertreatment and overtreatment in real-life clinical practice; the Loire Valley Atrial Fibrillation Project Chest 140 4 2011 911 917
14. S.H. Wang, Y.C. Kang, C.C. Wang, and et al. Annual atrial tachyarrhythmia burden determined by device interrogation in patients with cardiac implanted electronic devices is associated with a risk of ischaemic stroke independent of known risk factors Eur J Cardiothorac Surg 47 5 2015 840 846
15. T. Sanna, H.C. Diener, R.S. Passman, and et al. Cryptogenic stroke and underlying atrial fibrillation N Engl J Med 370 26 2014 2478 2486
16. M.A. Ritter, S. Kochhauser, T. Duning, and et al. Occult atrial fibrillation in cryptogenic stroke: detection by 7-day electrocardiogram versus implantable cardiac monitors Stroke 44 5 2013 1449 1452
17. A.C. Flint, N.M. Banki, X. Ren, V.A. Rao, and A.S. Go Detection of paroxysmal atrial fibrillation by 30-day event monitoring in cryptogenic ischemic stroke: the Stroke and Monitoring for PAF in Real Time (SMART) Registry Stroke 43 10 2012 2788 2790
18. N.R. Desai, A.A. Krumme, S. Schneeweiss, and et al. Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications Am J Med 127 11 2014 1075 1082.e1
19. J.C. Lauffenburger, J.F. Farley, A.K. Gehi, D.H. Rhoney, M.A. Brookhart, and G. Fang Factors driving anticoagulant selection in patients with atrial fibrillation in the United States Am J Cardiol 115 8 2015 1095 1101
20. G.Y. Lip, R. Nieuwlaat, R. Pisters, D.A. Lane, and H.J. Crijns Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation Chest 137 2 2010 263 272
21. C.T. January, L.S. Wann, J.S. Alpert, and et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society Circulation 130 23 2014 e199 e267
22. S.R. Collins, P.W. Rasmussen, M.M. Doty, and S. Beutel The rise in health care coverage and affordability since health reform took effect: findings from the Commonwealth Fund Biennial Health Insurance Survey, 2014 Issue Brief (Commonw Fund) 2 2015 1 16
23. S.J. Connolly, M.D. Ezekowitz, S. Yusuf, and et al. Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
24. C.B. Granger, J.H. Alexander, J.J. McMurray, and et al. Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 11 2011 981 992
25. F. Laliberte, W.W. Nelson, P. Lefebvre, J.R. Schein, J. Rondeau-Leclaire, and M.S. Duh Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients Adv Ther 29 8 2012 675 690
26. F. Laliberte, B.K. Bookhart, W.W. Nelson, and et al. Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism Patient 6 3 2013 213 224
27. D. Caldeira, A. Vaz-Carneiro, and J. Costa The impact of dosing frequency on medication adherence in chronic cardiovascular disease: systematic review and meta-analysis Rev Port Cardiol 33 7-8 2014 431 437
28. P. Harper, L. Young, and E. Merriman Bleeding risk with dabigatran in the frail elderly N Engl J Med 366 9 2012 864 866
29. J.W. Eikelboom, L. Wallentin, S.J. Connolly, and et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial Circulation 123 21 2011 2363 2372
30. K. Uchino, and A.V. Hernandez Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials Arch Intern Med 172 5 2012 397 402
31. S.H. Hohnloser, J. Oldgren, S. Yang, and et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial Circulation 125 5 2012 669 676
32. N. Schoof, J. Schnee, G. Schneider, and et al. Characteristics of patients with non-valvular atrial fibrillation using dabigatran or warfarin in the US Curr Med Res Opin 30 5 2014 795 804
33. Y. Xu, A.M. Holbrook, C.S. Simpson, D. Dowlatshahi, and A.P. Johnson Prescribing patterns of novel oral anticoagulants following regulatory approval for atrial fibrillation in Ontario, Canada: a population-based descriptive analysis CMAJ Open 1 3 2013 E115 E119
34. B.A. Steinberg, D.N. Holmes, J.P. Piccini, and et al. Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation J Am Heart Assoc 2 6 2013 e000535
35. R. Sorensen, G. Gislason, C. Torp-Pedersen, and et al. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study BMJ Open 3 5 2013 e002758
36. E.R. Zell, L.F. McCaig, B.A. Kupronis, R.E. Besser, and A. Schuchat A comparison of the National Disease and Therapeutic Index and the National Ambulatory Medical Care Survey to evaluate antibiotic usage Proceedings of the Survey Research Methods Section, American Statistical Association 2000 American Statistical Association Alexandria, VA
37. A. Higashi, S. Zhu, R.S. Stafford, and G.C. Alexander National trends in ambulatory asthma treatment, 1997-2009 J Gen Intern Med 26 12 2011 1465 1470
38. J. Avorn The relative cost-effectiveness of anticoagulants: obvious, except for the cost and the effectiveness Circulation 123 22 2011 2519 2521